Claim OwnershipReachMD CME
Subscribed: 196Played: 7,533
Subscribe
© Copyright 2026 ReachMD. All rights reserved.
Description
Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.
486 Episodes
Reverse
CME credits: 0.25
Valid until: 30-01-2027
Claim your CME credit at https://reachmd.com/programs/cme/progress-in-breast-cancer-care-translating-sabcs-data-into-practice/48989/
This online educational activity equips clinicians with up-to-date, practice-changing insights from SABCS 2025. Experts review pivotal data across early-stage and metastatic breast cancer, including advances in HER2- and TROP2-directed ADCs, and discuss how these findings can meaningfully inform treatment selection. Participants will learn how to apply new evidence to expand therapeutic options, improve patient outcomes, and navigate emerging safety and quality of life considerations.=
CME credits: 0.25
Valid until: 31-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/when-topicals-fail-the-new-ipc-consensus-every-clinician-should-know/39967/
This podcast reviews the International Psoriasis Council (IPC) 2025 guidance on reclassifying psoriasis severity and redefining failure of topical therapies. Clinical features such as high-impact disease sites, failure of topical treatment, or BSA >10% all factor into whether patients are candidates for systemic therapy in this new guidance. Despite broad endorsement, many clinicians remain uncertain about applying the new framework. This activity aims to raise awareness, clarify updated criteria, and align practice with current evidence supporting earlier use of IL-23 and IL-17 inhibitors in appropriate patients.=
CME credits: 1.00
Valid until: 11-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/Minimal-Hepatic-Encephalopathy-Hiding-in-Plain-Sight/39787/
This series of brief episodes focuses on the early recognition and clinical management of hepatic encephalopathy (HE). Drs. Arun Jesudian and Nancy Reau examine subtle signs that may indicate minimal or covert HE and offer strategies for timely diagnosis. The discussion covers practical tools for detection, the role of nutrition and pharmacologic therapy, and evidence-based approaches to prevent progression and hospitalization. Emerging therapies and ongoing clinical trials are also discussed to highlight future directions in HE treatment.
CME credits: 1.00
Valid until: 11-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/Minimal-Hepatic-Encephalopathy-A-Covert-Operation/39788/
This series of brief episodes focuses on the early recognition and clinical management of hepatic encephalopathy (HE). Drs. Arun Jesudian and Nancy Reau examine subtle signs that may indicate minimal or covert HE and offer strategies for timely diagnosis. The discussion covers practical tools for detection, the role of nutrition and pharmacologic therapy, and evidence-based approaches to prevent progression and hospitalization. Emerging therapies and ongoing clinical trials are also discussed to highlight future directions in HE treatment.
CME credits: 1.00
Valid until: 11-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/The-Slippery-Slope-of-Overt-Hepatic-Encephalopathy/39789/
This series of brief episodes focuses on the early recognition and clinical management of hepatic encephalopathy (HE). Drs. Arun Jesudian and Nancy Reau examine subtle signs that may indicate minimal or covert HE and offer strategies for timely diagnosis. The discussion covers practical tools for detection, the role of nutrition and pharmacologic therapy, and evidence-based approaches to prevent progression and hospitalization. Emerging therapies and ongoing clinical trials are also discussed to highlight future directions in HE treatment.
CME credits: 1.00
Valid until: 11-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/Treatment-of-Hepatic-Encephalopathy-When-What-How-and-Why/39790/
This series of brief episodes focuses on the early recognition and clinical management of hepatic encephalopathy (HE). Drs. Arun Jesudian and Nancy Reau examine subtle signs that may indicate minimal or covert HE and offer strategies for timely diagnosis. The discussion covers practical tools for detection, the role of nutrition and pharmacologic therapy, and evidence-based approaches to prevent progression and hospitalization. Emerging therapies and ongoing clinical trials are also discussed to highlight future directions in HE treatment.
CME credits: 1.00
Valid until: 11-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/Treatment-of-Hepatic-Encephalopathy-Primary-vs-Secondary-Prophylaxis/39791/
This series of brief episodes focuses on the early recognition and clinical management of hepatic encephalopathy (HE). Drs. Arun Jesudian and Nancy Reau examine subtle signs that may indicate minimal or covert HE and offer strategies for timely diagnosis. The discussion covers practical tools for detection, the role of nutrition and pharmacologic therapy, and evidence-based approaches to prevent progression and hospitalization. Emerging therapies and ongoing clinical trials are also discussed to highlight future directions in HE treatment.
CME credits: 1.00
Valid until: 11-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/Optimizing-Care-of-the-Hospitalized-Patient-With-Overt-Hepatic-Encephalopathy/39792/
This series of brief episodes focuses on the early recognition and clinical management of hepatic encephalopathy (HE). Drs. Arun Jesudian and Nancy Reau examine subtle signs that may indicate minimal or covert HE and offer strategies for timely diagnosis. The discussion covers practical tools for detection, the role of nutrition and pharmacologic therapy, and evidence-based approaches to prevent progression and hospitalization. Emerging therapies and ongoing clinical trials are also discussed to highlight future directions in HE treatment.
CME credits: 1.00
Valid until: 11-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/Current-Treatment-of-Hepatic-Encephalopathy-Is-It-Meeting-Our-Patients-Needs/39793/
This series of brief episodes focuses on the early recognition and clinical management of hepatic encephalopathy (HE). Drs. Arun Jesudian and Nancy Reau examine subtle signs that may indicate minimal or covert HE and offer strategies for timely diagnosis. The discussion covers practical tools for detection, the role of nutrition and pharmacologic therapy, and evidence-based approaches to prevent progression and hospitalization. Emerging therapies and ongoing clinical trials are also discussed to highlight future directions in HE treatment.
CME credits: 1.00
Valid until: 11-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/advances-in-the-oreatment-of-overt-hepatic-encephalopathy-whats-in-the-pipeline/39794/
This series of brief episodes focuses on the early recognition and clinical management of hepatic encephalopathy (HE). Drs. Arun Jesudian and Nancy Reau examine subtle signs that may indicate minimal or covert HE and offer strategies for timely diagnosis. The discussion covers practical tools for detection, the role of nutrition and pharmacologic therapy, and evidence-based approaches to prevent progression and hospitalization. Emerging therapies and ongoing clinical trials are also discussed to highlight future directions in HE treatment.
CME credits: 1.00
Valid until: 11-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/Hepatic-Encephalopathy-More-Common-Than-You-Think/39786/
This series of brief episodes focuses on the early recognition and clinical management of hepatic encephalopathy (HE). Drs. Arun Jesudian and Nancy Reau examine subtle signs that may indicate minimal or covert HE and offer strategies for timely diagnosis. The discussion covers practical tools for detection, the role of nutrition and pharmacologic therapy, and evidence-based approaches to prevent progression and hospitalization. Emerging therapies and ongoing clinical trials are also discussed to highlight future directions in HE treatment.
CME credits: 0.50
Valid until: 10-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/advances-in-treatment-of-hypoparathyroidism-importance-of-genetic-testing-for-autosomal-dominant-hypocalcemia-type-1/36097/
This CME activity focuses on enhancing clinician recognition and management of autosomal dominant hypocalcemia type 1 (ADH1). Learners will explore the pathophysiology and clinical manifestations of ADH1, understand barriers to timely diagnosis, gain practical strategies for implementing and interpreting genetic testing, and evaluate emerging therapies—such as calcilytics—that target CaSR mutations. By improving diagnostic accuracy, enabling timely and evidence-based interventions, and improving knowledge of emerging treatments, this activity aims to advance clinical outcomes for patients with ADH1. =
CME credits: 0.50
Valid until: 04-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/taking-action-against-rsv-no-child-unprotected/39307/
This three-part educational activity reviews the burden of respiratory syncytial virus (RSV) and evidence-based strategies to prevent disease in infants and young children. Chapter 1 examines the epidemiology of RSV and outlines current prophylactic options, including maternal vaccination and the monoclonal antibodies nirsevimab (approved 2023) and clesrovimab (approved 2025). Chapter 2 summarizes American Academy of Pediatrics (AAP) recommendations with guidance on timing, maternal vaccination status, coadministration, and the importance of hospital-based immunization for newborns. Chapter 3 focuses on effective parent–clinician communication, emphasizing shared decision-making, addressing concerns and misinformation, and supporting timely immunization to reduce RSV-related morbidity and mortality.=
CME credits: 0.25
Valid until: 03-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/early-action-in-obesity-transforming-practice-improving-outcomes/36273/
Expert faculty Drs. Luca Busetto and Kirsi H. Pietiläinen discuss the importance of early intervention in obesity management to prevent progression and obesity related complications. They examine the evolving therapeutic landscape, including GLP-1 and GIP-based medications like semaglutide and tirzepatide. The conversation highlights real-world evidence and addresses the shift from weight-centric to holistic clinical approaches, as seen in updated European and Canadian guidelines. Monitoring strategies—including satiety, nutritional status, physical activity, and side effects—are explored as key elements in long-term obesity care. The dialogue underscores the chronic nature of obesity and the importance of patient-centered care. =
CME credits: 0.25
Valid until: 02-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/rethinking-schizophrenia-treatment-through-muscarinic-modulation/37103/
In this Chairperson’s Perspective, Dr. Jose Rubio and Dr. Jonathan Meyer explore the evolving landscape of schizophrenia treatment through muscarinic receptor modulation. They compare the mechanisms of action, efficacy, and side effect profiles of muscarinic antipsychotics, such as xanomeline-trospium, with traditional dopamine D2 antagonists. The discussion addresses key clinical considerations for transitioning between dopaminergic and muscarinic therapies, including cholinergic burden and cross-titration timing. This expert dialogue provides relevant guidance for clinicians aiming to incorporate muscarinic therapies into personalized treatment plans for schizophrenia.=
CME credits: 1.00
Valid until: 02-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/future-mcrc-directions-enhancing-anti-egfr-therapy-with-novel-combination-strategies/48870/
This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.
CME credits: 0.25
Valid until: 26-11-2026
Claim your CME credit at https://reachmd.com/programs/cme/a-clear-horizon-in-plaque-psoriasis-an-update-on-investigational-oral-therapies/37867/
Among patients with moderate to severe plaque psoriasis, oral formulations of therapies is often a preferred route of administration, particularly among those with a fear of needles, which can negatively impact patent compliance. However, the currently available oral small-molecule therapies apremilast and deucravacitinib have demonstrated lower levels of skin clearance relative to biologics for the treatment of plaque psoriasis. Investigation into novel oral small-molecule therapies is ongoing, such as next-generation TYK2 inhibitors and the first-in-class investigational targeted oral peptide icotrokinra, which selectively targets IL-23 receptor signaling. These therapies have demonstrated dramatically improved clinical responses versus comparators and may significantly impact the current treatment paradigm for plaque psoriasis. =
CME credits: 0.25
Valid until: 19-11-2026
Claim your CME credit at https://reachmd.com/programs/cme/igan-management-into-practice-evolving-guidelines-targeted-therapies/37238/
Dr. Jürgen Floege, co-chair of the KDIGO Work Group, and Dr. Jörg Latus review the updated KDIGO 2025 guidelines for managing immunoglobulin A nephropathy (IgAN) and IgA vasculitis (IgAV), which emphasize diagnostic criteria, proteinuria-based treatment thresholds, and revised therapeutic goals. The discussion focuses on the new KDIGO proteinuria treatment goal of <0.3 g/d and the use of combination therapy targeting immune modulation and CKD management. In addition, they highlight the use of Nefecon, a disease-modifying therapy now recommended as a first-line treatment where approved. =
CME credits: 0.25
Valid until: 18-11-2026
Claim your CME credit at https://reachmd.com/programs/cme/engaging-your-patient-shared-decision-making-in-hf-with-lvef40/29910/
Enhance your ability to apply shared decision-making in patients with HF and LVEF ≥40%. Through real-world clinical vignettes, Dr. Scott Solomon illustrates how to uncover patient goals, clearly communicate risks and benefits, and build collaborative treatment plans. The session emphasizes early use of SGLT2 inhibitors and finerenone to reduce hospitalizations, improve quality of life, and optimize long-term outcomes. =
CME credits: 0.50
Valid until: 14-11-2026
Claim your CME credit at https://reachmd.com/programs/cme/navigating-the-therapeutic-landscape-of-platinum-resistant-ovarian-cancer/37667/
Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the tumor-specific expression of CDH6 to deliver potent cytotoxic agents directly to cancer cells while sparing healthy tissue. Two such agents, raludotatug deruxtecan and CUSP06, are currently under active investigation. In this activity, Drs. Joyce Liu and Kathleen Moore review the rationale for CDH6-directed ADCs in platinum-resistant ovarian cancer, the supporting clinical data from these agents, and the relevance of these findings to clinical practice.
Comments
Download from Google Play
Download from App Store
United States